Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update
| Autor: | Priya Patel, Robert S. Phillips, Lillian Sung, Jacqueline Flank, Andrea D. Orsey, Paula D. Robinson, Jennifer R. Madden, Carol Portwine, Paul Gibson, Jennifer Thackray, L. Lee Dupuis, Mark T. Holdsworth, Jason L. Freedman |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Quinuclidines Adolescent Nausea Vomiting Pediatrics 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Neoplasms medicine Humans Preschool Intensive care medicine Child Aprepitant business.industry Palonosetron Infant Hematology Guideline Isoquinolines Pediatric cancer Systematic review Oncology 030220 oncology & carcinogenesis Child Preschool Pediatrics Perinatology and Child Health Practice Guidelines as Topic Female Serotonin Antagonists medicine.symptom business medicine.drug Chemotherapy-induced nausea and vomiting |
| Zdroj: | Paediatrics Publications |
| ISSN: | 1545-5017 1545-5009 |
| Popis: | This update of the 2013 clinical practice guideline provides clinicians with guidance regarding the use of aprepitant and palonosetron for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in children. The recommendations were based on three systematic reviews. Substantive changes were made to the guideline recommendations including the inclusion of palonosetron to the 5-HT3 antagonists recommended for children receiving highly emetogenic chemotherapy (HEC) and the recommendation of aprepitant for children 6 months of age or older receiving HEC. To optimize CINV control in children, future work must focus on closing critical research gaps. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text